Scholarlink

<p>Prostate cancer (PCa) remains a&#xa0;leading cause of cancer-related morbidity and mortality in men. Over the past decades, the incidence has risen in all age groups. Prostate-specific membrane antigen (PSMA)-based theranostics, which involve the use of PSMA-targeting radiopharmaceuticals for both diagnostic imaging and therapeutic applications, have become integral in the management of patients with metastatic castration-resistant prostate cancer (mCRPC). The field has witnessed a&#xa0;substantial and continuously expanding body of scientific literature, encompassing case reports, original research, systematic reviews and also clinical guidelines. The objective of this joint statement is to enhance awareness of PSMA theranostics and underscore their critical role in contemporary precision oncology. We aim to provide a&#xa0;comprehensive yet practical perspective on the current landscape of PSMA-based diagnostic and therapeutic modalities, offering a&#xa0;consensus-driven approach to their clinical application.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Use of 177Lu prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月4日

查看全文
  • Siroos Mirzaei,
  • Gregor Schweighofer-Zwink,
  • Heidemarie Ofner,
  • Jasmin Bektic,
  • Harun Fajkovic,
  • Eisabeth von Guggenberg,
  • Anton Ponholzer,
  • Gero Kramer,
  • Lukas Lusuardi,
  • Michael Gabriel,
  • Tatjana Traub-Weidinger,
  • Marcus Hacker,
  • Shahrokh F. Shariat

摘要

Prostate cancer (PCa) remains a leading cause of cancer-related morbidity and mortality in men. Over the past decades, the incidence has risen in all age groups. Prostate-specific membrane antigen (PSMA)-based theranostics, which involve the use of PSMA-targeting radiopharmaceuticals for both diagnostic imaging and therapeutic applications, have become integral in the management of patients with metastatic castration-resistant prostate cancer (mCRPC). The field has witnessed a substantial and continuously expanding body of scientific literature, encompassing case reports, original research, systematic reviews and also clinical guidelines. The objective of this joint statement is to enhance awareness of PSMA theranostics and underscore their critical role in contemporary precision oncology. We aim to provide a comprehensive yet practical perspective on the current landscape of PSMA-based diagnostic and therapeutic modalities, offering a consensus-driven approach to their clinical application.